Neural Therapeutics Inc.
NURL
CNSX
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -89.97% | 118.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -89.11% | 110.73% | |||
| Operating Income | 89.11% | -110.73% | |||
| Income Before Tax | -137.11% | 118.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -137.11% | 118.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -137.11% | 118.14% | |||
| EBIT | 89.11% | -110.73% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -121.43% | 116.09% | |||
| Normalized Basic EPS | 92.86% | -75.00% | |||
| EPS Diluted | -121.43% | 116.09% | |||
| Normalized Diluted EPS | 92.86% | -75.00% | |||
| Average Basic Shares Outstanding | 77.05% | 12.14% | |||
| Average Diluted Shares Outstanding | 77.05% | 12.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||